Keywords
cancer
Khorana score
thromboprophylaxis
How to Cite
Abstract
Introduction. Venous thromboembolism (VTE) is a common complication of cancer patients. The Khorana predictive model stratifies risk and identifies patients who benefit from thromboprophylaxis. Objectives. To evaluate the usefulness of the Khorana score for VTE prophylaxis. Correlate the risk of the Khorana score with the risk of the COMPASS CAT and ONKO TEV score. Materials and methods. Observational, retrospective, analytical study, January 2020 to January 2022. Inclusion: > 18 years, recently diagnosed cancer prior to starting treatment. Exclusion: relapse, previous anticoagulation and arterial thrombosis. Variables included in the three risk scores were evaluated. Results. 221 patients. 64.3% female. Average age 57.3 years. Average follow-up 18 months. 30.3% high risk tumors (gynecological, lung, lymphoma, bladder and testicle) and 6.8% very high risk (pancreas and stomach). 54.7% overweight/obese. Khorana score 54.76% (n: 121) moderate risk of VTE, 37.10% (n: 82) low risk and 8.14% (n: 18) high risk. In high-risk Khorana patients 8.14% (n: 18), only 16.75% (n: 3) received prophylaxis. 56 (25.34%) patients developed VTE, mean of 4 months from diagnosis. Pulmonary thromboembolism and deep vein thrombosis were the most frequent presentations. Khorana showed high specificity for predicting thrombosis (92.7%) but low sensitivity (10.7%). COMPASS CAT and ONKO TEV identified more patients at high risk, 41 (73.25%), and 17 (30.3%) respectively. Discussion. The Khorana score showed high specificity but low sensitivity to predict thrombosis in our population. Although ONKO TEV has a greater coincidence with Khorana, in those with low or moderate risk COMPASS CAT could contribute patients to the high-risk group.
References
Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. doi: 10.1182/bloodadvances.2020003442.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327.
Moore R, Adel N, Riedel E y col. High incidence of thromboembolic events in patients treated with cisplatin based chemotherapy. A large retrospective analysis. J Clin Oncol. 2011;29:3466-73. doi: 10.1200/JCO.2011.35.5669.
Ay C, Dunkler D, Marosi C y col. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-82. doi: 10.1182/blood-2010-02-270116.
Mandala M, Clerici M, Corradino I y col. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol. 2012;23:1416-21.doi 10.1093/annonc/mdr524.
Gerotziafas G, Thaier A, Spyropoulos A y col. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. COMPASS CAT Working Group. The Oncologist. 2017;22:1222-1231. doi: 10.1634/theoncologist. 2016-0414.
Cella C, Di Minno G, Carlomagno C y col. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV study. TheOncologist. 2017;22:1-8. doi: 10.1634/theoncologist.2016-0246.
Pozner R, Giumelli C, Puente D y col. Actualización año 2022 Grupo CAHT RAT: Trombosis asociada a cáncer. 2022. https://www.grupocaht.com/trombosis-asociada a-cancer/.
Mulder F, Horváth-Puhó E, Van Es N y col. Venous thromboembolism in cancer patients: a population- based cohort study. Blood. 2021;137:1959-69. doi: 10.1182/ blood.2020007338.
Khorana A. Cancer-associated thrombosis: updates
and controversies. Hematology Am Soc Hematol Educ Program. 2012;12(1):626-30. doi: 10.1182/asheducation-2012.1.62.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327.
Farge D, Frere C, Connors J y col. The International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Lancet Oncol. 2022;23:334-47. doi: 10.1016/S1470-2045(22)00160-7.
Lyman GH, Carrier M, Ay C et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. doi: 10.1182/bloodadvances.2020003442.
Muñoz Martín A, Font Puig C, Navarro Martín L y col. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014;16:1079-90. doi: 10.1007/s12094-014-1238-y.
Carrier M, Abou-Nassar K, Mallick R y col. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719.
Khorana AA, Soff GA, Kakkar AK y col. CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.
Zhou W, Chen S, Yang J y col. Accuracy of the COMPASS CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis. J Thromb Thrombolysis. 2024 Oct;57(7):1193-1205.
Abdel-Razeq H, Sharaf B, Al-Jaghbeer MJ y col. COMPASS CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CKRAM study. J Thromb Thrombolysis. 2023;56: 447-453.
Cella CA, Djulbegovic B, Hozo I y col. Comparison of Khorana vs. ONKOTEV predictive score to individualize anticoagulant prophylaxis in outpatients with cancer. Eur J Cancer. 2024 Sep;209:114234. doi:
1016/j.ejca.2024.114234.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar